Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6070 and I-DXd in Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
NCT06780137Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Modality
- Prophylactic Vaccines, Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
A Phase 2 trial of gocatamig, ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Feb 2025; status: recruiting.
02
Drugs
gocatamigifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06780137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780137.